$103.4 M
IPIX Mkt cap, 31-Oct-2017Innovation Pharmaceuticals Net income (Q3, 2018)-11.5 M
Innovation Pharmaceuticals EBIT (Q3, 2018)-11.3 M
Innovation Pharmaceuticals Cash, 31-Mar-20181.3 M
Innovation Pharmaceuticals Financials
Innovation Pharmaceuticals Income Statement
Annual
| USD | FY, 2016 |
|---|---|
R&D expense | 9 m |
General and administrative expense | 1.9 m |
Operating expense total | 10.9 m |
EBIT | (12.7 m) |
Interest expense | 202 k |
Interest income | 4 k |
Pre tax profit | (12.9 m) |
Net Income | (12.9 m) |
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|
R&D expense | 1.9 m | 2.3 m | 1.8 m | 2.1 m | 3 m | 2.3 m | 2.7 m | 3.2 m | 9.5 m |
General and administrative expense | 244 k | 275 k | 339 k | 352 k | 249 k | 362 k | 344 k | 331 k | 889 k |
Operating expense total | 2.2 m | 2.6 m | 2.2 m | 2.5 m | 3.3 m | 2.6 m | 3 m | 3.5 m | 11.4 m |
EBIT | (2.7 m) | (2.8 m) | (2.5 m) | (3.3 m) | (3.7 m) | (3 m) | (3.3 m) | (3.9 m) | (11.4 m) |
Interest expense | 51 k | 51 k | 51 k | 50 k | 51 k | 51 k | 50 k | 51 k | 152 k |
Interest income | 1 k | 1 k | 1 k | 1 k | 1 k | 1 k | 1 k | 1 k | |
Pre tax profit | (2.8 m) | (2.9 m) | (2.6 m) | (3.3 m) | (3.7 m) | (3 m) | (3.4 m) | (3.9 m) | (11.5 m) |
Net Income | (2.8 m) | (2.9 m) | (2.6 m) | (3.3 m) | (3.7 m) | (3 m) | (3.4 m) | (3.9 m) | (11.5 m) |
Innovation Pharmaceuticals Balance Sheet
Annual
| USD | FY, 2016 |
|---|---|
Cash | 6.3 m |
Current Assets | 6.7 m |
Total Assets | 11.4 m |
Accounts Payable | 42.2 m |
Current Liabilities | 8.5 m |
Total Liabilities | 8.5 m |
Additional Paid-in Capital | 57 m |
Retained Earnings | (54 m) |
Total Equity | 3 m |
Financial Leverage | 3.9 x |
Quarterly
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q3, 2018 |
|---|---|---|---|---|---|---|---|
Cash | 7.1 m | 9.5 m | 10.8 m | 7.8 m | 6.2 m | 5.3 m | 1.3 m |
Current Assets | 7.2 m | 9.6 m | 11.4 m | 8 m | 6.4 m | 5.8 m | 1.5 m |
Total Assets | 12.5 m | 14.9 m | 17.1 m | 13.5 m | 11.9 m | 11.3 m | 5.8 m |
Current Liabilities | 8 m | 7.7 m | 7.3 m | 7.5 m | 7.6 m | 8.4 m | 9.5 m |
Total Liabilities | 9.5 m | ||||||
Additional Paid-in Capital | 36.9 m | 42.3 m | 47.8 m | 49.8 m | 51.3 m | 53.6 m | 77.3 m |
Retained Earnings | (32.4 m) | (35.2 m) | (38.1 m) | (43.7 m) | (47.1 m) | (50.8 m) | (81.1 m) |
Total Equity | 4.5 m | 7.1 m | 9.8 m | 6 m | 4.3 m | 2.9 m | (3.7 m) |
Financial Leverage | 2.8 x | 2.1 x | 1.7 x | 2.2 x | 2.8 x | 3.9 x | -1.5 x |
Innovation Pharmaceuticals Cash Flow
Annual
| USD | FY, 2016 |
|---|---|
Net Income | (12.9 m) |
Accounts Payable | 1.7 m |
Cash From Operating Activities | (9.9 m) |
Purchases of PP&E | (68 k) |
Cash From Investing Activities | (414 k) |
Cash From Financing Activities | 8.2 m |
Interest Paid | 235 k |
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|
Net Income | (2.8 m) | (2.9 m) | (2.6 m) | (3.3 m) | (3.7 m) | (3 m) | (3.4 m) | (3.9 m) |
Innovation Pharmaceuticals Ratios
| USD | Y, 2018 |
|---|---|
Financial Leverage | -1.5 x |
Report incorrect company information
